Ensysce Biosciences Completes Cy Biopharma Acquisition and Raises Financing

What happened

Ensysce Biosciences, Inc. (NASDAQ: ENSC), a San Diego-based pharmaceutical company focused on pain treatments, announced on August 6, 2026 that it completed a stock-for-stock acquisition of Cy Biopharma, according to the company's press release distributed via ACCESS Newswire and reported by StreetInsider, Yahoo Finance, and StockTitan.

Under the merger, Cy Biopharma equity interests were exchanged for 282,122 shares of Series C non-voting convertible preferred stock, according to Investing.com. Cy Biopharma holders will own approximately 75% of the combined entity, based on the company's announcement. Cy Biopharma is now a wholly owned subsidiary of Ensysce, according to TipRanks.

The acquisition brings Ensysce a clinical-stage neuroplastogenic therapy called CY200, which has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS), according to the company's press release.

In conjunction with the acquisition, Ensysce announced up to $77 million in private financing. This consists of a $21.5 million PIPE (private investment in public equity), $17.1 million in cash, and up to $38.6 million tied to milestone achievements, according to the company's announcement. The financing was led by Ally Bridge and other investors, per the press release.

Ensysce shares closed at $0.487 on the event date, down 5.62% from the previous close of $0.516, according to price data. One outlet, QuiverQuant, noted the stock had surged earlier, but the closing price reflected a decline for the day.

What this means

The transaction is structured as a reverse merger, where Cy Biopharma's shareholders end up owning roughly three-quarters of Ensysce. This is a common way for a private company to become publicly traded without a traditional initial public offering (IPO). Ensysce remains the legal acquirer, but control shifts to the former Cy Biopharma owners.

The Series C non-voting convertible preferred stock issued to Cy holders can be converted into common stock later, but it carries no voting rights initially. This structure allows the deal to close without triggering a shareholder vote that a direct issuance of voting common stock might require.

CY200 is a neuroplastogenic therapy, meaning it aims to promote the repair or regrowth of nervous system tissue. It has been granted Orphan Drug Designation by the FDA for CRPS, a chronic pain condition that typically affects an arm or leg after an injury, surgery, or stroke. Orphan Drug Designation is given to therapies for rare diseases affecting fewer than 200,000 people in the U.S.; it provides incentives like tax credits, fee waivers, and seven years of market exclusivity if the drug is approved.

The financing package is split into stages. The $21.5 million PIPE provides immediate capital from private investors buying stock at a negotiated price. The $17.1 million in cash is likely from existing Ensysce resources or concurrent investments. The $38.6 million milestone portion will be paid only if the company achieves specific development or regulatory goals, such as completing a Phase 2 clinical trial. The company stated the funds will be used to advance CY200 through Phase 2 testing.

For a small biotech like Ensysce, this deal is transformative but also highly dilutive to existing shareholders. After issuing preferred stock convertible into a large number of common shares, current Ensysce investors will own a much smaller percentage of the company. The stock's 5.62% decline on the announcement day may reflect this dilution concern, though the sources do not explicitly state the reason for the price move.

About Ensysce and Cy Biopharma

Ensysce Biosciences is a clinical-stage pharmaceutical company that, prior to this acquisition, focused on developing opioid therapies with built-in abuse deterrents. Its lead programs aimed to reduce the risk of overdose and misuse of prescription painkillers.

Cy Biopharma is a private company whose lead asset, CY200, is a neuroplastogenic therapy for Complex Regional Pain Syndrome. CRPS is a poorly understood condition that causes severe, persistent pain, often after a minor injury. Treatment options are limited, and the market for CRPS therapies is estimated at over $1 billion, according to the company's description of the opportunity.

With the acquisition complete, Ensysce now holds a pipeline that includes both its existing opioid-safety programs and CY200, giving it a Phase 2-ready asset in a new therapeutic area.